OcuSciences’ eye health diagnostic instrument gains EU CE clearance
October 16, 2025
The clearance led to the deployment of the instrument across various medical facilities in the UK and Europe.
The clearance led to the deployment of the instrument across various medical facilities in the UK and Europe.
Florida Atlantic University has expanded its NeuroInnovate Center, becoming the first institution globally to integrate advanced MRI and focused ultrasound technologies into a single, unified platform for both preclinical and clinical research. This breakthrough will accelerate the development of non-invasive treatments for neurological disorders such as Alzheimer’s, Parkinson’s and more.
A friend’s struggles with arthritis and the finger braces used to manage it inspired research by a Carnegie Mellon University student that could make it easier for patients to follow rehabilitation plans, speed up recovery times and help people manage chronic conditions.
The influenza A virus (IAV) has been the cause of six major flu pandemics, responsible for 50 to 100 million deaths globally. In the U.S. alone, it is estimated that despite seasonally updated vaccines, IAV infections still lead to 140,000 to 710,000 hospitalizations and 12,000 to 52,000 deaths annually.
Faulty versions of the LMNA gene can cause a wide range of health problems, including heart muscle disease (dilated cardiomyopathy) and muscle weakness (muscular dystrophies). Many of these diseases are caused by single-point mutations, which are changes to one DNA “letter” (base).
OKLAHOMA CITY and CHICAGO, Oct. 14, 2025 /PRNewswire/ — Simergent, a privately held company dedicated to advancing treatment for patients with kidney failure, today announced 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the company’s Archimedes™ automated peritoneal dialysis (APD) system for the treatment of patients with End Stage Kidney Disease (ESKD) in clinical and home settings.
Researchers at Cincinnati Children’s Hospital Medical Center in collaboration with Roche, have developed a next-generation human liver organoid microarray platform that could help predict which drugs may cause harmful immune reactions in some people.
Three presentations at ESMO 2025 will demonstrate Lunit SCOPE IO’s value in predicting immunotherapy response in colorectal, kidney, and lung cancer patients.
Researchers have improved the ability of wearable health devices to accurately detect when a patient is coughing, making it easier to monitor chronic health conditions and predict health risks such as asthma attacks. The advance is significant because cough-detection technologies have historically struggled to distinguish the sound of coughing from the sound of speech and nonverbal human noises.
Health data helped identify kids in the ER who are likely to develop sepsis within 48 hours